The human cathelicidin antimicrobial peptide LL-37 is involved in various aspects of skin biology, including protection against infection, wound healing, and also in psoriasis. The tight regulation of apoptosis is critical in tissue repair and its deregulation is a part of the psoriasis phenotype. Despite being involved in cell death of several cell types, virtually nothing is known about the function of LL-37 in keratinocyte apoptosis. Here we report that LL-37 peptide protects primary human keratinocytes and HaCaT cells from apoptosis induced by the topoisomerase I inhibitor camptothecin (CAM). In particular, pretreatment with LL-37 significantly decreased caspase-3 activity after CAM-treatment. Expression profiling of keratinocytes treated with LL-37 identified the upregulation of cyclooxygenase-2 (COX-2) expression, a gene implicated in protection from apoptosis. In addition to inducing COX-2 expression, LL-37 stimulated the production of its product, prostaglandin E-2 (PGE-2). Moreover, LL-37 induced the expression of inhibitor of apoptosis-2 (IAP-2), implicated in the COX-2/PGE-2 antiapoptotic pathway. Pretreatment with a selective COX-2 inhibitor abolished the antiapoptotic effect of LL-37 and reduced IAP-2 expression implicating that the antiapoptotic effect of LL-37 in keratinocytes is mediated by a COX-2-dependent mechanism involving IAP-2. Thus, overexpression of LL-37 may contribute to reduced keratinocyte apoptosis in conditions such as psoriasis.
INTRODUCTION
Cathelicidins are a family of antimicrobial proteins found in most mammalian species. They consist of a highly conserved N-terminal domain, cathelin, and a variable C-terminal peptide which is proteolytically released upon activation (Zanetti et al., 1995; Sorensen et al., 2001) . The single human member of this family, 18 kDa human cationic antimicrobial protein, hCAP18, is mainly produced by leukocytes and epithelial and mucosal cells (Agerberth et al., 1995; Frohm et al., 1997; Sorensen et al., 1997; Bals et al., 1998; Frohm Nilsson et al., 1999; De et al., 2000) . Its cationic C-terminal 37 amino-acid domain, LL-37 displays broad antimicrobial activity (Dorschner et al., 2001; Zasloff, 2002) mediated through direct interaction with and disruption of the microbial cell membrane (Oren et al., 1999; Ramanathan et al., 2002) . In addition to being antimicrobial, LL-37 is implicated in diverse biological processes, such as chemotaxis, cytokine production, histamine release, and angiogenesis (Koczulla et al., 2003; Braff et al., 2005; Shaykhiev et al., 2005) . Furthermore, human cathelicidin antimicrobial peptide 18 kDa/LL-37 is highly expressed during normal wound healing (Dorschner et al., 2001; Heilborn et al., 2005) , displays growth factor-like properties enhancing the in vitro proliferation and migration of human keratinocytes, and is involved in reepithelization of wounds (Heilborn et al., 2003 (Heilborn et al., , 2005 . The signaling pathways induced by LL-37 are not fully known, but current work identifies at least one receptor for LL-37, the purinergic receptor P2X 7 (Elssner et al., 2004) . Moreover, it was recently shown that LL-37 converts self-DNA into a danger signal triggering autoimmunity in psoriasis (Lande et al., 2007) . At high concentrations, exceeding 13 mM, LL-37 is cytotoxic to eukaryotic cells (Johansson et al., 1998) by disrupting membrane integrity. However, at low concentrations LL-37 has been shown to modulate contrasting effects on apoptosis in different mammalian cells types (Barlow et al., 2006; Lau et al., 2006; Nagaoka et al., 2006) . Suppression or induction of apoptosis mediated by LL-37 seems to be dependent on peptide concentration and/or cell type. The function of LL-37 in human keratinocyte apoptosis has not been studied.
Given the previously reported contrasting effects on apoptosis mediated by LL-37, the present study was undertaken to investigate whether LL-37, in view of its putative role in wound healing, would affect apoptosis pathways in human keratinocytes. We report here that treatment with LL-37 at a noncytotoxic concentration protected keratinocytes from undergoing apoptosis and regulated the expression of antiapoptotic genes such as inhibitor of apoptosis protein-2 (IAP-2) and cyclooxygenase-2 (COX-2).
RESULTS

LL-37 suppresses camptothecin-induced apoptosis in keratinocytes
To explore the hypothesis that LL-37 is involved in apoptosis in primary normal human keratinocytes (NHKs), we examined the effect of LL-37 on cells exposed to camptothecin (CAM). This drug is a topoisomerase I inhibitor and is broadly used experimentally as an apoptosis-inducing agent (Pessina et al., 2001) . After treatment with CAM, membrane integrity and DNA fragmentation were analyzed by flow cytometry using two different methods. The first method differentiates between apoptosis and necrosis measuring increased permeability of the cell membrane to the dye YO-PRO as a marker for apoptosis and propidium iodide staining (PI) as a marker for necrosis. By the second method, the DNA content in ethanol-permeabilized cells was analyzed by PI staining with apoptotic cells showing less amount of DNA due to fragmentation.
When exposed to 6 mM of CAM for 24 hours, HaCaT cells as well as NHK displayed a staining pattern and a DNA profile characteristic of apoptosis ( Figure 1 ). NHK cells pretreated with LL-37 showed a significant reduction in the number of apoptotic cells compared with cells treated with CAM alone (Figure 1a -e) (n ¼ 3, Pp0.001). A similar effect was seen for necrotic cells after pretreatment with 2 mM LL-37. Also in HaCaT cells LL-37 treatment significantly (n ¼ 2; Po0.05) reduced apoptosis induced by CAM (Figure 2 ).
To validate these findings with a different method, we performed DNA content analysis of NHK cells to determine the extent of DNA fragmentation before and after treatment with CAM, LL-37, or their combination (Figure 3 ). In accordance with the previous findings, the fraction of NHK cells with DNA fragmentation induced by CAM, was significantly reduced (n ¼ 3; Po0.01) by pretreatment with 1 or 2 mM LL-37 (Figure 3 ). Although treatment with CAM induced the number of cells with a low DNA content (sub 2N) from 1.5% (Figure 3a ) to 14.7% (Figure 3d ), pretreatment with 1 or 2 mM LL-37 suppressed it to 7.2% (Figure 3e ) or 4.4% (Figure 3f ), respectively, demonstrating that LL-37 protects cells from CAM-induced cell death (Figure 3) . Interestingly, treatment of cell with 1 or 2 mM LL-37 alone also suppressed the fraction of sub-2N cells from 1.5% (Figure 3a ) to 0.9% (Figure 3b and c), although this change was not statistically significant due low number of sub-2N cells under normal cell culture conditions. Taken together, LL-37 is effective in protecting keratinocytes from CAM-induced cell death.
LL-37 inhibits caspase-3 activation in human primary keratinocytes As caspase-3 is one of the key proteins in the apoptosis pathway and an early indicator of apoptosis, we measured caspase-3 activity in keratinocytes upon treatment with CAM and/or LL-37. We found that CAM significantly (n ¼ 3; Po0.01) induced caspase-3 activation 24 hours after treatment (Figure 4) . When NHK cells were pretreated with LL-37, a significant (n ¼ 3; Pp0.01) and concentration-dependent decrease in CAM-induced activation of caspase-3 was found (Figure 4 ) demonstrating that LL-37 inhibits caspase-3 activation in keratinocytes.
LL-37 upregulates the expression of antiapoptotic genes in keratinocytes
To gain a more complete understanding of how LL-37 affects apoptosis in keratinocytes, we used gene array technology to profile gene expression patterns in NHK cells 6 hours after treatment with 2 mM LL-37. Analysis of data using the ''Significance Analysis of Microarrays'' algorithm identified 74 significantly differentially expressed genes (false discovery rateo5%) between keratinocytes treated with LL-37 or medium alone. The genome-wide portrait of LL-37-induced changes in the gene expression profile of keratinocytes will be presented elsewhere (C.I. Chamorro et al., unpublished data). Among differentially expressed genes, we focused specifically on those previously linked to apoptosis. We found that LL-37 induced a twofold upregulation of the prostaglandin endoperoxide synthetase gene (COX-2) in keratinocytes, a gene important in the regulation of apoptosis (Dempke et al., 2001; Cheuk et al., 2002; Slice et al., 2005; Papadimitriou et al., 2007) .
To validate the results obtained by the microarray analysis, we next performed quantitative real-time PCR analysis of COX-2 mRNA expression in LL-37-treated NHK cells ( Figure  5a ). In accordance with the results of the microarray, treatment with 2 mM LL-37 induced a significant (n ¼ 3; Pp0.05), more than twofold increase in COX-2 mRNA levels already after 6 hours, and sustained up to 24 hours ( Figure 5a ).
As the porcine homologue of LL-37 (PR-39) is known to induce the expression of the IAP-2 (Wu et al., 2004) we also set out to determine whether LL-37 was able to modulate the expression of IAP-2 in keratinocytes by analyzing its expression by reverse transcriptase-PCR. We found that treatment of NHK cells with 2 mM LL-37 induced a significant (n ¼ 3; Pp0.05), almost twofold increase in IAP-2 mRNA expression 6 and 12 but not 24 hours after LL-37 treatment ( Figure 5b ). Thus, high expression of COX-2 at 24 hours does not ensure a high IAP-2 mRNA level at later time points (Figure 5b ). It could be that this difference in mRNA levels reflects different turnover of COX-2 and IAP-2 mRNAs in the cell or alternatively that sustained activation of IAP-2 induces a negative feedback loop. It is also important to note that even though mRNA levels of IAP-2 go down, protein levels may persist and thereby explaining the antiapoptotic effects. These results demonstrate that LL-37 upregulates the expression of the antiapoptotic genes COX-2 and IAP-2 in NHKs.
LL-37 induces COX-2-dependent induction of PGE-2 in keratinocytes
To determine whether the increased levels of COX-2 correlated with prostaglandin E-2 (PGE-2) production in primary keratinocytes, we stimulated the cells with different concentrations of LL-37 and measured the levels of PGE-2 in cell culture supernatants at different time points ( Figure 6 ). We found that LL-37 induced a significant (n ¼ 3; Po0.05), Figure 3 . LL-37 treatment suppresses DNA fragmentation in human primary keratinocytes. Apoptosis was induced by 6 mM CAM in subconfluent primary keratinocytes following pretreatment with 1 or 2 mM of LL-37 or medium alone for 24 hours. DNA fragmentation was assessed by propidium iodide (PI) staining after 24 hours of CAM treatment. One representative flow cytometry histogram from one of two independent experiments showing DNA fragmentation in cells treated with (a) medium alone, (b) 1 mM of LL-37, (c) 2 mM of LL-37, (d) 6 mM CAM, (e) 6 mM CAM and 1 mM of LL-37, and (f ) 6 mM CAM and 2 mM of LL-37. Cells were stained with PI and analyzed by flow cytometry to detect nonapoptotic (2N to 4N) and apoptotic populations (sub 2N). (g) Box plot summarizing two independent experiments each performed with triplicates.
www.jidonline.org 3 time-and concentration-dependent increase of PGE-2 levels in the culture media ( Figure 6 ). Pretreatment of cells with a selective COX-2 inhibitor, SC-791 (Tripp et al., 2003) significantly (Pp0.05) decreased the levels of PGE-2 induced by LL-37 indicating that the LL-37-induced PGE-2 production was mediated by COX-2 ( Figure 6 ). Together these results indicate that LL-37 modulates both expression and activity of COX-2 in keratinocytes.
Inhibition of COX-2 suppresses the antiapoptotic effects of LL-37 in keratinocytes
Given the known antiapoptotic effects of prostaglandins we tested whether the inhibition of COX-2 and therefore the COX-2-dependent increase in PGE-2 production would affect the antiapoptotic effect of LL-37 in keratinocytes. NHK cells were pretreated for 30 minutes with 25 nM of the specific COX-2 inhibitor, SC-791, and then treated with CAM, LL-37, or both in combination. Apoptosis was assessed by measuring caspase-3 activity ( Figure 7 ). As anticipated, CAM treatment induced a significant (n ¼ 3; Po0.05) increase in caspase-3 activity, whereas pretreatment with LL-37 significantly (n ¼ 3; Po0.05) suppressed the CAM-induced caspase-3 activation (Figure 7) . Moreover, pretreatment of cells with the specific COX-2 inhibitor suppressed the antiapoptotic effects of LL-37. These results demonstrate that the antiapoptotic effects induced by LL-37 in keratinocytes are mediated -at least in part -through COX-2.
IAP-2 induction by LL-37 is dependent on COX-2 activity
Different studies have suggested that PGE-2 can modulate the expression of members of the inhibitor apoptosis proteins family (IAPs) (Roy et al., 1997; Nishihara et al., 2003) . To determine whether the upregulation of IAP-2 by LL-37 was mediated by COX-2 activity, we pretreated NHK cells with the specific COX-2 inhibitor SC-791 before addition of LL-37 ( Figure 8 ). 2 mM LL-37 induced a significant (n ¼ 3; Po0.01), almost twofold increase in IAP-2 mRNA expression in comparison with medium-treated cells 6 hours after treatment Figure 6 . LL-37 induces the release of PGE-2 in a COX-2-dependent manner in human primary keratinocytes. Keratinocytes were treated with either 2 or 4 mM of LL-37, medium, or in combination with the COX-2 inhibitor (SC-791). Cells were pretreated with the specific COX-2 inhibitor SC-791 for 30 minutes, followed by incubation with 2 mM of LL-37 or medium alone for 6 hours. Supernatants were collected after 3, 6, 16, 24, and 48 hours and assayed for PGE-2 levels by ELISA. Results from one representative experiment performed with triplicates are shown.
( Figure 8a ). In contrast, pretreatment of keratinocytes with the COX-2 inhibitor prevented LL-37-induced increase of IAP-2 mRNA (Po0.05) (Figure 8a ). To investigate whether the observed effects were dependent on PGE-2, the main product of COX-2, we treated primary keratinocytes with PGE-2 and analyzed IAP-2 expression (Figure 8b) . Results of quantitative real-time PCR analyses revealed a trend that treatment of keratinocytes with PGE-2 upregulated the expression of IAP-2 (Figure 8b ). These results suggest that the antiapoptotic effects induced by LL-37 in keratinocytes are mediated -at least in part -by COX-2 and IAP-2.
DISCUSSION
In the present study we investigated the function of the antimicrobial peptide LL-37 in keratinocyte apoptosis. We found that LL-37 protected human keratinocytes from CAMinduced apoptosis. The antiapoptotic effect was associated with a decrease in caspase-3 activity. Furthermore, we showed that LL-37 upregulated the expressions of COX-2 and IAP-2, a member of the antiapoptotic family of proteins. Moreover, LL-37 increased PGE-2 production in keratinocytes in a COX-2-dependent manner. In addition, we demonstrated that inhibition of COX-2 suppressed both the antiapoptotic effects of LL-37 and the expression of IAP-2. These results suggest that the antiapoptotic effects induced by LL-37 in keratinocytes are mediated -at least in part -by COX-2 and IAP-2. Contrasting effects on apoptosis have been described for LL-37 (Barlow et al., 2006) . At high concentrations (above 20 mM) LL-37 has cytotoxic effects on eukaryotic cells, through mechanisms involving disruption of the cell membrane, mitochondrial injury, and cytochrome c release (Aarbiou et al., 2006) Moreover, high concentrations of LL-37 induced apoptosis in epithelial carcinoma cell lines (Okumura et al., 2004) , and in air way epithelial cell lines (Barlow et al., 2006; Lau et al., 2006) . In contrast, here we found that LL-37 peptide protected primary human keratinocytes and HaCaT cells from topoisomerase I inhibitorinduced apoptosis. In agreement with our findings, antiapoptotic effects of LL-37 have been demonstrated in neutrophils as a result of LL-37-mediated expression of antiapoptotic proteins and decrease in caspase-3 activation (Barlow et al., 2006; Nagaoka et al., 2006) . Thus, the contrasting effects of LL-37 on cell death may depend on multiple factors including peptide concentration, the presence of serum components and most importantly the cell type. Therefore, distinct apoptotic responses may occur due to variations in signaling and processing of LL-37 in different cells.
COX-2 is usually expressed at low or undetectable levels in most cells, but is induced in response to proinflammatory cytokines, growth factors, and tumor promoters (Dubois et al., 1998) . COX-2 produces PGE-2 that affects cell proliferation (Shao et al., 2003; Krysan et al., 2005; Papadimitriou et al., 2007) and decreases apoptosis in different cell types (Liou et al., 2007; Papadimitriou et al., 2007) . COX-2 is frequently overexpressed in cancer and is implicated in tumor progression (Chen et al., 2001; Dempke et al., 2001; Barnes et al., 2006; Yalcin et al., 2007) . We found that LL-37 induces COX-2 expression and PGE-2 production in NHKs and that its antiapoptotic function is partially mediated by this pathway. Moreover, we found that the upregulation of IAP-2 by LL-37 could be prevented by the pretreatment of cells with COX-2 inhibitor. Furthermore, PGE-2, the main product of COX-2 could also induce IAP-2 expression. However, when we added all three compounds (LL-37 þ COX-2 inhibitor þ PGE-2) together to the cells there was no convincing rescue of the COX-2 inhibition. A possible explanation for this is that the combined treatment had a negative effect on the cells. Still, taken together, our data indicate that LL-37 upregulates IAP-2 by a COX-2-dependent mechanism. Interestingly, LL-37 is overexpressed in several types of cancer and (Heilborn et al., 2005; Coffelt et al., 2008; von Haussen et al., 2008) its overexpression induces biological processes relevant for tumor growth and progression including neoangiogenesis (Koczulla et al., 2003) , and (a) Human primary keratinocytes were treated with the specific COX-2 inhibitor (SC-791) at 25 nM or medium alone for 30 minutes and further incubated with 2 mM LL-37 or medium alone for 6 hours. IAP-2 mRNA levels were analyzed by RT-PCR and normalized against the medium-treated sample. Means±SD are shown. *Po0.05; **Po0.01. (b) Human primary keratinocytes were treated with 10 mM PGE-2 for 6 hours. IAP-2 mRNA levels were analyzed by RT-PCR and normalized against the medium-treated sample. Means±SD are shown.
www.jidonline.org 5 increased cell proliferation and migration (Heilborn et al., 2005; Coffelt et al., 2008; von Haussen et al., 2008) . Our data suggest that the induction of COX-2 expression by LL-37 may play a role in cancer development. The exact mechanism by which LL-37 induces the expression of COX-2 is at present unknown and deserves further investigation in the future. LL-37 is emerging as a key player in skin biology being implicated in wound healing (Heilborn et al., 2003; Shaykhiev et al., 2005; Carretero et al., 2008) and is overexpressed in psoriasis with a putative pathogenetic role in disease manifestation (Lande et al., 2007) . The tight regulation of apoptosis in keratinocytes is critical for the maintenance of normal epidermal turnover and for wound healing. Experimental data suggest that inhibition of apoptosis in human keratinocytes accelerates reepithelialization and wound closure (Xue et al., 2004) .
Interestingly, LL-37 modulated the expression of IAP-2 by a mechanism, which seems to be dependent of COX-2 activity. These results are in agreement with studies showing that PGE-2 derived from COX-2 can modulate the expression of members of the IAPs (Roy et al., 1997; Nishihara et al., 2003) . IAP-2 is widely recognized as a key regulator of apoptosis and it operates through the direct inactivation of caspase-3 (Roy et al., 1997) . The porcine orthologue of LL-37 (PR-39) has also been shown to protect human cells from apoptosis through the induction of IAP-2 expression suggesting that the regulation of apoptosis by cathelicidins is conserved through evolution (Wu et al., 2004; Ross et al., 2007) . These in vitro results could have in vivo relevance, as both LL-37 and IAP-2 were recently reported to be overexpressed in psoriatic skin (Tovar-Castillo et al., 2007) . It was suggested that LL-37 may be involved in the resistance to apoptosis of dermal endothelial cells by the induction of IAP-2 (Tovar-Castillo et al., 2007) . We found in the present study that LL-37 increased in vitro IAP-2 expression in human keratinocytes; which may enhance keratinocyte survival and resistance to apoptosis.
On the basis of our findings LL-37 protects human keratinocytes from apoptosis by the activation of the COX-2 pathway. Therefore, LL-37 (or its receptor) may be a promising therapeutic target for the treatment of diseases characterized by high LL-37 expression and low apoptosis such as cancer and psoriasis.
MATERIALS AND METHODS
Cell culture
Foreskin Epidermal keratinocytes (Cascade Biologics, Eugene, OR) were cultured in Epilife basal medium (Cascade Biologics) supplemented with 60 mM calcium chloride, 0.2% (v/v) bovine pituitary extracts (BPE), 5 mg ml À1 bovine insulin, 0.18 mg ml À1 hydrocortisone, 5 mg ml À1 bovine transferrin, 0.2 ng ml À1 human epidermal growth factor, 100 U ml À1 penicillin G, 100 mg ml À1 streptomycin sulfate, and 0.25 mg ml À1 Ampotericin B (all Cascade Biologics) at 37 1C and 5% CO 2 . Cells were passage weekly using 0.025% (w/v) trypsin and 0.01% (w/v) EDTA.
HaCaT keratinocytes (a kind gift from R Fusenig) were cultured in DMEM (Gibco-BRL Technology, Paisley, UK) supplemented with 10% fetal calf serum (HyClone, Boule Nordic AB, Huddinge, Sweden), 2 mM glutamine, penicillin (50 U l À1 ; Gibco-BRL), and streptomycin (50 mg ml À1 ; Gibco-BRL).
Drug treatment and apoptosis evaluation
Cell treatment. A total of 25,000 cells per well were plated in six-well plates. At 48 hours after plating, cells were treated with different concentrations of LL-37. Each treatment was performed in triplicate. The peptide was diluted in medium (DMEM with 5% fetal calf serum for HaCaT cells and Epilife basal medium supplemented with 0.1% fetal calf serum for NHK cells). Cells were treated for 24 hours, where after the topoisomerase I inhibitor CAM (Sigma Chemical Co., St. Louis, MO) was added to a final concentration of 6 mM. Cells were then incubated further for 24 hours before analysis. The specific COX-2 inhibitor SC-791 (Calbiochem, Darmstadt, Germany) was used at 25 nM concentration in culture medium and was applied to the cells at least 30 minutes before of LL-37 treatment.
Evaluation of apoptosis by flow cytometry
Two apoptotic parameters, loss of membrane integrity, and decrease of DNA, were evaluated by flow cytometry.
Evaluation of membrane integrity. After stimulation with LL-37 and treatment with CAM, cells were harvested by trypsinization. The cells were then washed in cold Dulbecco's phosphate-buffered saline and counted in a hemocytometer (Hausser Scientific, Horsham, PA). Cell density was adjusted to 1 Â 10 6 cells per ml in phosphate-buffered saline. Apoptosis was evaluated by staining with PI and YO-PRO dye (Molecular Probes, Eugene, OR). Stained cells were analyzed on a FACScan (Becton Dickinson, San Jose, CA). Cells were gated for analysis on the basis of the forward (FSC) and side (SSC) light-scattering characteristics. Analysis of cells expressing YO-PRO and PI was performed using Cell Quest software (Becton Dickinson), which provided percentages of YO-PRO and PI-positive cells. Cells that stained green with YO-PRO were considered apoptotic (Idziorek et al., 1995) . Cells that also stained red, with PI, were necrotic. Live, viable cells take up little or no dye. 
Caspase-3 activity assay
Caspase-3 enzymatic activity was measured using the fluorometric substrate DEVD-AMC (Ac-DEVD-AMC; Sigma-Aldrich, St Louis, MO) (100 mM) as previously described (Zhang et al., 2005) . Briefly cell lysates were combined in a reaction buffer (100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 10% sucrose, 5 mM dithiothreitol, 1% NP-40, and 0.1% CHAPS (pH 7.25) and added to a microtiter plate. The cleavage of the fluorogenic substrate was monitored by AMC liberation in a Fluoroscan II plate reader (Labsystems, Stockholm, Sweden). Fluorescence units were converted to pmol of AMC using a standard curve generated from free AMC. Data were analyzed by linear regression and are displayed as caspase-3 activity (pmol AMC release per minute).
Quantitative real-time PCR
Total RNA was isolated from cells after different treatments according to the manufacturer's directions by using the Qiagen RNasy kit (Operon Biotechnologies, Cologne, Germany). Reverse transcription was performed with a first-strand synthesis kit (Amersham Biosciences, St. Leon-Rot, Germany). The expression of 18S, cIAP-2 and COX-2 was quantified using Quantitative realtime PCR (DNA Engine Opticon 2 system; MJRsearch Incorporate).
The following primers were used: human 18S sense, 
Microarray
A microarray containing 14,000 human oligo 70 mers (Operon; Qiagen), printed twice and produced at the SweGen DNA Microarray Resource Center at Lund University was used to evaluate the NHK response to LL-37. Total RNA was isolated as described before. cDNA probes were prepared by reverse transcription from 20 mg of total RNA, labeled with the fluorescent cyanine dyes Cy3 and Cy5. The protocols employed for probe labeling, purification, and hybridization were performed as described previously (TolletEgnell et al., 2001) . Analysis of the microarray results was performed using the Significance Analysis of Microarrays tool (Stanford tools) as described earlier (Tusher et al., 2001) .
ELISA
Levels of PGE-2 in the culture supernatants of LL-37 treated and untreated NHK during time periods were measured with a commercially available ELISA using a PGE-2 High Sensitivity Immunoassay kit (R&D Systems, Minneapolis, MN) Supernatants were centrifuged to remove cell debris and were stored at -80 1C until assayed. The results were expressed as pg PGE-2 per ml.
Statistical analysis
All experiments were performed in triplicate a minimum of three times. Means and standard deviations were calculated. The significance of the differences among the treatments was estimated by using analysis of variance (ANOVA) and a Welsh two-sample t-test (Team, 2005) . A P-value of 0.05 was considered statistically significant.
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